Access cutting-edge juvenile myelomonocytic leukemia treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access juvenile myelomonocytic leukemia specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related juvenile myelomonocytic leukemia treatment provided free
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
Check if you qualify for this juvenile myelomonocytic leukemia clinical trial in Washington Dc, DC
If you're searching for juvenile myelomonocytic leukemia treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced juvenile myelomonocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.